KEYNOTE-756: Pembrolizumab Plus Chemo in Early-Stage ER+/HER2- Breast Cancer
November 9th 2023Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.
Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer
January 12th 2021Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.
Dr. Erika P. Hamilton on Difficulties of Treating Brain Metastases in Breast Cancer
February 19th 2016Hamilton says there are currently not very many "good" drugs for treating these metastases. She adds that the mainstay for treating these metastases is usually some form of radiation therapy, such as whole brain radiation.
Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast Cancer
August 28th 2015Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.
ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast Cancer
June 15th 2015Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.